AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 191 min read$ELVN

Hohl Benjamin sold $353K of ELVN

Hohl Benjamin (CHIEF FINANCIAL OFFICER) sold 6,018 shares of Enliven Therapeutics, Inc. (ELVN) at an average of $58.58 ($58.35–$59.35, $0.35M total) across 2 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hohl Benjamin
Published Aug 19, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ELVN
Neutral
medium confidence
Mentioned
$ELVN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, offering limited new insight for traders.

02

Market read

Routine insider transaction with low trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-19

Background

Form 4 filing reports an insider sale by the CFO of Enliven Therapeutics, a US-listed biotech.

Company-level read

Ticker impact

$ELVNNeutralMedium confidence
Context

CFO Hohl Benjamin sold 6,018 shares for $352,551 on 2026-08-17 via a 10b5-1 plan.

Expected impact

Potential slight dip or flat price action.

Evidence & confidence

Sale size is modest relative to float and disclosed under a pre-arranged plan, limiting informational content.

Market effects

Sector

Minimal impact on biotech sector; typical insider transaction.

Regional

None beyond the company's own shares.

Global

None

Counterpoint

What could challenge this read

Insider sell could be interpreted as lack of confidence, but may simply be liquidity planning.

Key entities

  • company
    Enliven Therapeutics, Inc.

    Biotech firm (NASDAQ: ELVN) whose CFO sold shares.

  • person
    Hohl Benjamin

    Chief Financial Officer of Enliven Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ELVN insider trading history →

Related articles

AUG 5
$ELVNMed

Enliven Therapeutics, Inc. (ELVN): Results of Operations and Financial Condition

Enliven Therapeutics, Inc. (ELVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignme

SEC EDGAR 8-K6 min
JUN 12
$ELVNMedAI 8/10

Enliven Therapeutics Shares Rise 9%

Enliven Therapeutics (ELVN) shares rose 8.92% to $43.96 on Friday after the company priced an upsized public offering expected to raise about $400 million in gross proceeds, according to the article. Enliven sold 8.93 million shares at $37.50 plus pre-funded warrants. Volume was 2.49 million shares versus a 1.20 million average.

rttnews.com2 min